Aspergillus GM LFA

Over 30 million people are at risk of invasive aspergillosis each year because of corticosteroid use or other therapies, and over 300.000 patients develop it annually.

The disease is common in high risk patients with:
• Hematological malignancies
• Chemotherapy-induced neutropenia
• Allogeneic HSCT (stem cell transplant)
• Solid organ transplant (primarily lung)

Key Advantages of the Aspergillus GM LFA:
• 30 Minute test time
• Simplified procedure
• High sensitivity and specificity
• Serum & BAL specimens
• Test more frequently/Eliminate batch testing

AF2003 Brochure

Please contact us if you need a specific product, we are meeting many customers’ unique requests.

Go to webshop

Your Cart